EP2396009A1 - Compositions for the treatment of aphthous stomatitis - Google Patents
Compositions for the treatment of aphthous stomatitisInfo
- Publication number
- EP2396009A1 EP2396009A1 EP10708593A EP10708593A EP2396009A1 EP 2396009 A1 EP2396009 A1 EP 2396009A1 EP 10708593 A EP10708593 A EP 10708593A EP 10708593 A EP10708593 A EP 10708593A EP 2396009 A1 EP2396009 A1 EP 2396009A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- solution
- acid
- homeopathic
- components
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Definitions
- the present invention relates to compositions for the treatment of aphthous stomatitis.
- said compositions have proved to be remarkably effective not only for the surprising swiftness to which aphthous stomatitis recedes, but also for the significant reduction in occurrence of the same over time.
- Aphthous stomatitis is an affection of the oral cavity involving the formation of one or more ulcers. They can even persist for several weeks, leave a scar after healing and can relapse in a few years or can recur continuously, with new lesions appearing before the previous ones have healed. This latter case is referred to as recurrent aphthous stomatitis whose occurrence frequency can lead to extreme cases wherein the affection becomes chronic. Aphthous stomatitis affects both sexes and, while observable at any age, it is more often seen in children and young people.
- Aphthous stomatitis is hence a specific pathology which presents with swelling, painful ulcers from pu ⁇ ctiform to 2.5cr ⁇ hsized in diameter, localized on the lips, cheeks, gums, palate and oral cavity floor.
- Three forms are known: minor, major and herpetiform.
- the minor form presents with small, painful, round and well-defined recurring ulcers, with raised margins surrounded by a reddened halo and a shallow necrotic central part.
- the major form is similar to the minor form but the ulcers are larger and deeper, often leaving scars, and can last for several weeks or months.
- the herpetiform form is the least common and is characterized by small and several ulcers.
- aphthous stomatitis The etiology of aphthous stomatitis is currently unknown, while the existence of factors favouring the onset thereof is known, such as conditions of nutrient deficiency, specifically vitamin B12, folic acid and iron, and of stress, local trauma, menstrual periods, hormonal dysfunction, gastrointestinal disturbances, celiac disease, drug taking, intestinal parasites, gastric and/or intestinal malabsorption, physical and mental tiredness, allergies, fever and use of amalgam in dental treatments.
- factors favouring the onset thereof is known, such as conditions of nutrient deficiency, specifically vitamin B12, folic acid and iron, and of stress, local trauma, menstrual periods, hormonal dysfunction, gastrointestinal disturbances, celiac disease, drug taking, intestinal parasites, gastric and/or intestinal malabsorption, physical and mental tiredness, allergies, fever and use of amalgam in dental treatments.
- factors favouring the onset thereof is known, such as conditions of nutrient deficiency
- a solution comprising: a) a zinc salt of a polyhydroxy acid having n carbon atoms, and b) a magnesium salt of a polyhydroxy acid having m carbon atoms, wherein n and m are, independently of each other, an integer from 3 to 10 and the components a) and b) are in a v/v ratio of 10:1 to 1:10.
- polyhydroxy acid it is meant an acid substituted by 1 to 9 hydroxy! groups
- 10:1 to 1 :10 it is meant a ratio based on a volume unit which varies from 10 volumes of component a) per 1 volume of component b) to 1 volume of component a) per 10 volumes of component b).
- the invention concerns a pharmaceutical formulation comprising said solution.
- the invention concerns a homeopathic product comprising said solution.
- the invention relates to the use of the solution for the treatment of aphthous stomatitis.
- the subject of the invention is therefore a solution comprising: a) a zinc salt of a polyhydroxy acid having n carbon atoms, and b) a magnesium salt of a polyhydroxy acid having m carbon atoms, wherein n and m are, independently of each other, an integer from 3 to 10 and the components a) and b) are in a v/v ratio of 10:1 to 1 :10.
- the combination of zinc and magnesium when vehicled in the form of a salt of polyhydroxy acid having 3 to10 carbon atom, is able to relieve the pain caused by aphthae in an extremely and advantageously short time period, even only a few hours after consumption, and is able to substantially reduce a further onset over time.
- the rate of recurrence of aphthous stomatitis is significantly reduced, up to two or three fold, compared to untreated aphthous stomatitis.
- said recurrence is progressively reduced, meaning that the frequency, both in time and in number, of each event diminishes by two or three fold compared to the frequency both in time and in number of the previous event.
- the components a) and b) are in a v/v ratio of 5;1 to 1 :5. More preferably, the components a) and b) are in a v/v ratio of 2:1 to 1 : 2. Even more preferably, the components a) and b) are in a v/v ratio of 1 :1.
- Suitable polyhydroxy acids are:
- n and m are, independently of each other, an integer from 5 to 8. More preferably, ⁇ and m are equal to each other. Even more preferably, both n and m are 6.
- said solution further comprises at least one inorganic magnesium salt and at least one inorganic zinc salt.
- said at least one inorganic magnesium salt and at least one inorganic zinc salt are, independently of each other, a chloride, sulphide or carbonate.
- said solution is an alcoholic solution. More preferably, said solution is a 30% alcoholic solution. Even more preferably said solution is a 30% ethano) solution.
- the solution of the invention is used as a medicament.
- said solution is used in the treatment of aphthous stomatitis.
- the selection and suitable combination of the components a) and b) has proved to be particularly effective not only in relieving the pain caused by the aphthae within an extremely and advantageously short time period, even only a few hours after consumption, but also in substantially reducing healing time, as well as subsequent onset in time both in terms of the number of simultaneous aphthae and their recurrence over time.
- the faster the administration of solution of the invention after appearance of the aphthae the more remarkable the advantages attained.
- said solution is to be administered sublingualis
- this administration route enables aphthae healing times to be further shortened, thus more rapidly relieving the pain caused thereby.
- the solution is contacted with the mucous membrane and diffuses through the epithelium under the tongue, a region dense with blood vessels, and enters the circulation i.e. into the blood, more rapidly than for example by oral administration, while conveniently by-passing the stomach.
- the possibility of avoiding the passage through the stomach is appreciable not only in consideration of the vulnerability of the gastric mucosa, which is particularly delicate in very young and elderly subjects, but is also extremely desirable in cases of gastric malabsorption.
- the present invention relates to a sublingual formulation comprising the solution as above described and suitable pharmaceutically acceptable vehicles.
- the present invention relates to the use of the solution as above described for preparing a homeopathic product for treating aphthous stomatitis.
- the solution of the invention has also proved to be suitable for preparations according to homeopathic practice.
- said homeopathic product is to be administered sublingualis Indeed, similarly to the aforesaid, this administration route enables aphtha healing times to be further shortened for homeopathic products as well, thus more rapidly relieving the pain caused thereby.
- said homeopathic product is also suitable for treating aphthous stomatitis in the paediatric field, i.e. when administered to children suffering therewith.
- the present invention concerns a sublingual homeopathic product comprising the above described solution and suitable homeopathically acceptable vehicles.
- the components a) and b) are present independently of each other in homeopathic dilutions from 2 CH to 7 CH.
- homeopathic practice several types of dilutions are employed.
- the Hahnemannian centesimal dilutions (CH) indicate a 1 :100 ratio. They are prepared by adding one part of active substance to 99 parts of solvent. The mixture is subjected to vigorous succession, namely "dynamization", by a vibrating apparatus; in this manner the first Hahnemannian centesimal is produced, i.e. 1CH.
- DH decimal decimal dilutions
- said solution in said homeopathic product further comprises at least one inorganic magnesium salt and at least one inorganic zinc salt, each independently of the other in homeopathic dilutions from
- said inorganic salts potentiate the synergy, and hence efficacy, observed for the combination of components a) and b) conveniently in said dilutions, i.e. at advantageously very low concentrations.
- the components a) and b) are salts of a polyhydroxy acid having 6 carbon atoms. More preferably, said solution is an alcoholic solution comprising components a) and b) in a 1 :1 v/v ratio, double calcium magnesium carbonate, and zinc sulphide.
- said selection of compounds enables optimal results to be obtained under all considered viewpoints.
- the homeopathic product wherein said solution is an alcoholic solution comprising a Zn salt of 2,3,4,5,6-pentahydroxyhexanoic acid
- said homeopathic product is particularly suitable for the treatment of aphthous stomatitis in the paediatric field, i.e. when administered to children suffering therewith.
- the component a) was prepared by mixing 1 g of a zinc salt of a polyhydroxy acid and optionally 10 g of an inorganic zinc salt in 30% ethyl alcohol to obtain a total solution of 100 ml.
- the component b) was prepared by mixing 1 g of a magnesium salt of a polyhydroxy acid and optionally 0.1 g of an inorganic magnesium salt in 30% ethyl alcohol to obtain a total solution of 100 ml.
- the component a) was prepared by mixing 8 ml of a zinc salt of a polyhydroxy acid and optionally 7 ml of an inorganic zinc salt in 30% ethyl alcohol to obtain a total solution of 100 ml.
- the component a) was prepared by mixing 8 ml of a magnesium salt of a polyhydroxy acid and optionally 7 ml of an inorganic magnesium salt in 30% ethyl alcohol to obtain a total solution of 100 ml.
- the solution according to the present invention was obtained by mixing component a) and component b).
- a panel of 20 adult individuals affected by recurrent aphthous stomatitis were selected for whom the treatment with neither the known supplements also containing Zn and Mg nor treatment with a Zn salt of 2,3,4,5,6- pe ⁇ tahydroxyhexa ⁇ oic acid and a Mg salt of 2,3,4,5,6-pentahydroxyhexanoic acid taken alone and separately gave results of any kind.
- Example 14 To these 20 adult individuals 20 drops of the homeopathic product of Example 14 were administered sublingual ⁇ 3 times a day for 5 days.
- the homeopathic product of the invention has proved to be particularly indicated in the treatment of aphthous stomatitis, enabling pain to be rapidly mitigated and above all to heal aphthae and reduce their onset in terms of number and frequency with an efficacy never before noted, neither with known supplements nor with the components a) and b) consumed singly.
- a panel of 20 children aged between 2 and 5 years affected by recurrent aphthous stomatitis were selected for whom the treatment with neither the known supplements also containing Zn and Mg nor treatment with a Zn salt of 2,3,4,5,6- pentahydroxyhexanoic acid and a Mg salt of 2,3,4,5, 6- ⁇ entahydroxyhexanoic acid taken alone and separately gave results of any kind.
- 10 drops of the homeopathic product of Example 14 were administered sublingually 3 times a day for 5 days.
- the homeopathic product of the invention has proved to be particularly indicated in the paediatric treatment of aphthous stomatitis, enabling pain to be rapidly mitigated in children and above all to heal aphthae and reduce their onset in terms of number and frequency with an efficacy never before noted, neither with known supplements nor with components a) and b) consumed singly. From the detailed description and from the given working examples, the advantages achieved by the described solution, obtained according to the present invention, are evident.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compositions for the treatment of aphthous stomatitis are described comprising a) a zinc salt of a polyhydroxy acid and b) a magnesium salt of a polyhydroxy acid, wherein the components a) and b) are in a v/v ratio of 10:1 to 1 :10. In particular, said compositions have proved to be remarkably effective not only for the surprising swiftness to which the aphthous stomatitis heals, but also for the significant reduction in their subsequent recurrence in time.
Description
COMPOSITIONS FOR THE TREATMENT OF APHTHOUS STOMATITIS
Field of the invention
The present invention relates to compositions for the treatment of aphthous stomatitis. In particular, said compositions have proved to be remarkably effective not only for the surprising swiftness to which aphthous stomatitis recedes, but also for the significant reduction in occurrence of the same over time. State of the art
Aphthous stomatitis is an affection of the oral cavity involving the formation of one or more ulcers. They can even persist for several weeks, leave a scar after healing and can relapse in a few years or can recur continuously, with new lesions appearing before the previous ones have healed. This latter case is referred to as recurrent aphthous stomatitis whose occurrence frequency can lead to extreme cases wherein the affection becomes chronic. Aphthous stomatitis affects both sexes and, while observable at any age, it is more often seen in children and young people. Aphthous stomatitis is hence a specific pathology which presents with swelling, painful ulcers from puπctiform to 2.5crτhsized in diameter, localized on the lips, cheeks, gums, palate and oral cavity floor. Three forms are known: minor, major and herpetiform. The minor form presents with small, painful, round and well-defined recurring ulcers, with raised margins surrounded by a reddened halo and a shallow necrotic central part. The major form is similar to the minor form but the ulcers are larger and deeper, often leaving scars, and can last for several weeks or months. The herpetiform form is the least common and is characterized by small and several ulcers.
The etiology of aphthous stomatitis is currently unknown, while the existence of factors favouring the onset thereof is known, such as conditions of nutrient deficiency, specifically vitamin B12, folic acid and iron, and of stress, local trauma, menstrual periods, hormonal dysfunction, gastrointestinal disturbances, celiac disease, drug taking, intestinal parasites, gastric and/or intestinal malabsorption, physical and mental tiredness, allergies, fever and use of amalgam in dental treatments. For the treatment of aphthous stomatitis, it is known to take analgesics for
relieving pain and to undergo a cortisone therapy for controlling inflammation. These therapies, however, are unable to intervene in the causes that trigger aphthous stomatitis, being rather limited to prevent the inflammation from getting any worse. Moreover, cortisone drug administration cannot be continued for long periods particularly in cases where the affected individuals are children, and after it has ceased the ulcers unavoidably reoccur.
Also known are products in spray form for local topical application which form a protective layer on individual ulcers so that the same are isolated to hence facilitate their resorption. Alternatively, patches are known which &re to be applied onto the ulcers and, similarly to the spray, isolate them from contact with food and liquids. Even in this case, the aphthous stomatitis is treated after its onset to avoid contamination and prevent the inflammation from getting any worse. Therefore, the contraindications of cortisone therapy are overcome but only one ulcer per time is treated, simply by physically covering it.
In attempting to intervene at the problem underlying the aphthous stomatitis onset, it was also envisaged to use vitamins able to reduce inflammation. However, known vitamin complexes and food supplements have been also proved to be unsatisfactory as they minimize worsening of the ulcers, but are unable to heal them effectively and rapidly; nor are they able to prevent or even limit their further onset over time, either in terms of number of simultaneous aphthae or in terms of occurrence frequency.
It is therefore an object of the present invention to find a remedy for the treatment of aphthous stomatitis which is rapidly effective, well tolerated by the body, particularly in case of children, such as to limit as far as possible any unwanted side effects, and is able to reduce the number of aphthae and their recurrence over time.
Summary of the invention The above object has been achieved by a solution comprising: a) a zinc salt of a polyhydroxy acid having n carbon atoms, and b) a magnesium salt of a polyhydroxy acid having m carbon atoms, wherein n and m are, independently of each other, an integer from 3 to 10 and the components a) and b) are in a v/v ratio of 10:1 to 1:10.
For the purposes of the present invention, with the term "polyhydroxy acid" it is meant an acid substituted by 1 to 9 hydroxy! groups, and with the term Vv ratio of
10:1 to 1 :10" it is meant a ratio based on a volume unit which varies from 10 volumes of component a) per 1 volume of component b) to 1 volume of component a) per 10 volumes of component b).
In another aspect, the invention concerns a pharmaceutical formulation comprising said solution.
In a further aspect, the invention concerns a homeopathic product comprising said solution.
In a yet further aspect, the invention relates to the use of the solution for the treatment of aphthous stomatitis.
The characteristics and advantages of the present invention will be evident from the following detailed description and from the working examples given for illustrating and non-limiting purposes.
Detailed description of the invention
The subject of the invention is therefore a solution comprising: a) a zinc salt of a polyhydroxy acid having n carbon atoms, and b) a magnesium salt of a polyhydroxy acid having m carbon atoms, wherein n and m are, independently of each other, an integer from 3 to 10 and the components a) and b) are in a v/v ratio of 10:1 to 1 :10.
In this respect, it has been surprisingly found that the combination of zinc and magnesium, when vehicled in the form of a salt of polyhydroxy acid having 3 to10 carbon atom, is able to relieve the pain caused by aphthae in an extremely and advantageously short time period, even only a few hours after consumption, and is able to substantially reduce a further onset over time. In fact, it has been observed that the rate of recurrence of aphthous stomatitis is significantly reduced, up to two or three fold, compared to untreated aphthous stomatitis. Moreover, said recurrence is progressively reduced, meaning that the frequency, both in time and in number, of each event diminishes by two or three fold compared to the frequency both in time and in number of the previous event. By way of illustration only, and as will be seen from the following examples, it was found that individuals who manifested a plurality of aphthae about every 15 days, noted after treatment
with the solution of the invention that the aphthae reappeared surprisingly after not less than about two months and were fewer in number; after a subsequent treatment with the solution of the invention, the aphthae surprisingly reappeared after not less than about six months and were even fewer in number. Preferably, the components a) and b) are in a v/v ratio of 5;1 to 1 :5. More preferably, the components a) and b) are in a v/v ratio of 2:1 to 1 : 2. Even more preferably, the components a) and b) are in a v/v ratio of 1 :1. Suitable polyhydroxy acids are:
• 2-hydroxypropanoic acid
• 3-hydroχypropanoic acid
• 2-hydroxybutanoic acid
• 3-hydroxybutanoic acid
• 4-hydroxybutanoic acid
• 2-hydroxypentanoic acid
• 3-hydroxypentanoic acid
• 4-hydroxypentanoic acid
• 5-hydroxypentanoic acid
• 3,5-dihydroxypentanoic acid
• 4,5-dihydroxypentaπoic acid
• 3,4-dihydroχypentanoic acid
• 2,3,4-trihydroxypentanoic acid
• 2,3,4,5-tetrahydroxypentanoic acid
• 2-hydroxyhexanoic acid
• 3-hydroxyhexanoic acid
• 4-hydroxyhexanoic acid
• 5-hydroxyhexanoic acid
• 6-hydroχyhexanoic acid
• 2,2-dihydroxyheχanoic acid
• 3,5-dihydroxyhexanoic acid
• 4,5-dihydroxyhexanoic acid
• 3,5,6-trihydroχyhexanoic acid
• 4,5,6-trihydroxyhexanoic acid
• 2,3,4,5,6-pentahydroxyheχanoic acid
• 2-hydroxyheptanoic acid
• 3-hydroxyheptanoic acid
• 4-hydroxyheptanoic acid » 5-hydroxyheptanoic acid
• 6-hydroxyheptanoic acid
• 7-hydroxyheptanoic acid
• 3,5-dihydroxyheptanoic acid
• 3,5,7-trihydroxyheptanoic acid
• 2,3, 4,5,6, 7-hexahydroxyheptanoic acid - 2-hydrαxyαctanoic acid
• 3-hydroxyoctanoic acid
• 4-hydroxyαctanoic acid
• 5-hydroxyoctanoic acid
• 6-hydroxyoctanoic acid
• 7-hydroxyoctanoic acid
• 8-hydroxyoctanoic acid
• 2,8-dihydroxyoctanoic acid
• 6,8-dihydroxyoctanoic acid
• 4,5,6,7,8-pentahydroxyoctanoic acid
• 2,4,5,6,7-pentahydroxyoctanoic acid
• 2,4,5, 6,7,8-hexahydrσxyoctanoic acid
• 2,3,4,5,6,7,8-heptahydroxyoctaπoic acid
Preferably, in said polyhydroxy acids having π or m carbon atoms, n and m are, independently of each other, an integer from 5 to 8. More preferably, π and m are equal to each other. Even more preferably, both n and m are 6.
According to a preferred embodiment, said solution further comprises at least one inorganic magnesium salt and at least one inorganic zinc salt. According to a more preferred embodiment, said at least one inorganic magnesium salt and at least one inorganic zinc salt are, independently of each other, a chloride, sulphide or carbonate.
Preferably said solution is an alcoholic solution. More preferably, said solution is a
30% alcoholic solution. Even more preferably said solution is a 30% ethano) solution.
In another aspect, the solution of the invention is used as a medicament. In particular, said solution is used in the treatment of aphthous stomatitis. As will be seen from the examples that follow, the selection and suitable combination of the components a) and b) has proved to be particularly effective not only in relieving the pain caused by the aphthae within an extremely and advantageously short time period, even only a few hours after consumption, but also in substantially reducing healing time, as well as subsequent onset in time both in terms of the number of simultaneous aphthae and their recurrence over time. Moreover, the faster the administration of solution of the invention after appearance of the aphthae, the more remarkable the advantages attained.
Preferably, said solution is to be administered sublingualis In this respect, it has been observed that this administration route enables aphthae healing times to be further shortened, thus more rapidly relieving the pain caused thereby. The solution is contacted with the mucous membrane and diffuses through the epithelium under the tongue, a region dense with blood vessels, and enters the circulation i.e. into the blood, more rapidly than for example by oral administration, while conveniently by-passing the stomach. In this sense, the possibility of avoiding the passage through the stomach is appreciable not only in consideration of the vulnerability of the gastric mucosa, which is particularly delicate in very young and elderly subjects, but is also extremely desirable in cases of gastric malabsorption. This latter, as aforesaid, is one of the factors promoting onset of aphthous stomatitis, but is at the same time an obstacle to drug assimilation and hence also to any assimilation of the components of the solution of the invention, thus unavoidably compromising its effectiveness.
In the case of sublingual administration, absorption is of indirect type and the mechanism is passive diffusion. Compared to other administration routes, it is more advantageous as it also allows self-administration. Besides being rapid, the effect is also greater, as there is no loss of the components a) and b) before entering the bloodstream. In a further aspect, the present invention relates to a sublingual formulation
comprising the solution as above described and suitable pharmaceutically acceptable vehicles.
In a yet further aspect, the present invention relates to the use of the solution as above described for preparing a homeopathic product for treating aphthous stomatitis. As will be seen from the following examples, the solution of the invention has also proved to be suitable for preparations according to homeopathic practice. Preferably, said homeopathic product is to be administered sublingualis Indeed, similarly to the aforesaid, this administration route enables aphtha healing times to be further shortened for homeopathic products as well, thus more rapidly relieving the pain caused thereby. Moreover, it has been surprisingly observed that said homeopathic product is also suitable for treating aphthous stomatitis in the paediatric field, i.e. when administered to children suffering therewith.
In another aspect, the present invention concerns a sublingual homeopathic product comprising the above described solution and suitable homeopathically acceptable vehicles. Preferably, in said solution the components a) and b) are present independently of each other in homeopathic dilutions from 2 CH to 7 CH. According to homeopathic practice, several types of dilutions are employed. The Hahnemannian centesimal dilutions (CH) indicate a 1 :100 ratio. They are prepared by adding one part of active substance to 99 parts of solvent. The mixture is subjected to vigorous succession, namely "dynamization", by a vibrating apparatus; in this manner the first Hahnemannian centesimal is produced, i.e. 1CH. One part of the 1CH dilution, mixed in a fresh flask with 99 parts of solvent then dynamized, constitutes the 2CH and so forth until the 30CH as the maximum limit. The Hahnemmanian decimal dilutions (DH) are dilutions in a 1 :10 ratio, prepared by following exactly the same method as for Hahnemannian centesimals.
It should be noted that at the dilutions selected above the combination of components a) and b) is conveniently effective, being at the same time advantageously extremely safe and tolerable in view of the significantly reduced quantities of said components. In accordance with a preferred embodiment, said solution in said homeopathic
product further comprises at least one inorganic magnesium salt and at least one inorganic zinc salt, each independently of the other in homeopathic dilutions from
5 DH to 10 CH.
Indeed, said inorganic salts potentiate the synergy, and hence efficacy, observed for the combination of components a) and b) conveniently in said dilutions, i.e. at advantageously very low concentrations.
Preferably, in said solution the components a) and b) are salts of a polyhydroxy acid having 6 carbon atoms. More preferably, said solution is an alcoholic solution comprising components a) and b) in a 1 :1 v/v ratio, double calcium magnesium carbonate, and zinc sulphide. As will be seen from the following examples, said selection of compounds enables optimal results to be obtained under all considered viewpoints.
Particularly preferred is the homeopathic product wherein said solution is an alcoholic solution comprising a Zn salt of 2,3,4,5,6-pentahydroxyhexanoic acid
3CH and a Mg salt of 2,3,4,5,6-pentahydroxyheχanoic acid 3CH in a 1 :1 v/v ratio, double magnesium calcium carbonate 8CH, and zinc sulphide 8DH.
In addition, said homeopathic product is particularly suitable for the treatment of aphthous stomatitis in the paediatric field, i.e. when administered to children suffering therewith.
Working examples of the present invention are hereinafter given for illustrating and non-limiting purposes.
EXAMPLES
Examples 1-7
Preparation of formulations according to the present invention
The component a) was prepared by mixing 1 g of a zinc salt of a polyhydroxy acid and optionally 10 g of an inorganic zinc salt in 30% ethyl alcohol to obtain a total solution of 100 ml.
The component b) was prepared by mixing 1 g of a magnesium salt of a polyhydroxy acid and optionally 0.1 g of an inorganic magnesium salt in 30% ethyl alcohol to obtain a total solution of 100 ml.
The solution according to the present invention was obtained by mixing component a) and component b).
Examples of said solutions of the invention obtained according to the above process are given in the following table:
Examples 8-14
Preparation of homeopathic products according to the present invention
The component a) was prepared by mixing 8 ml of a zinc salt of a polyhydroxy acid and optionally 7 ml of an inorganic zinc salt in 30% ethyl alcohol to obtain a total solution of 100 ml.
The component a) was prepared by mixing 8 ml of a magnesium salt of a polyhydroxy acid and optionally 7 ml of an inorganic magnesium salt in 30% ethyl alcohol to obtain a total solution of 100 ml.
The solution according to the present invention was obtained by mixing component a) and component b).
Examples of said solutions of the invention obtained according to the aforesaid process are given in the following table:
Example 15
Evaluation of the results obtained by sublingual administration of the homeopathic product of Example 14 in adult individuals
Although all the formulations and homeopathic products prepared above were shown to be effective in the treatment of aphthous stomatitis, it was chosen to report the results attained with the homeopathic product of Example 14 as it enabled optimal results to be obtained according to all the considered viewpoints,
A panel of 20 adult individuals affected by recurrent aphthous stomatitis were selected for whom the treatment with neither the known supplements also containing Zn and Mg nor treatment with a Zn salt of 2,3,4,5,6- peπtahydroxyhexaπoic acid and a Mg salt of 2,3,4,5,6-pentahydroxyhexanoic acid taken alone and separately gave results of any kind.
To these 20 adult individuals 20 drops of the homeopathic product of Example 14 were administered sublingual^ 3 times a day for 5 days.
4-6 hours after the first consumption, 80% of said individuals noted a relief of pain caused by the aphthae and the ulcer healing beginning.
After 1 day, 100% of said individuals no longer felt any pain, while in 70% of them the aphthae had already completely healed.
One year after starting the treatment with the homeopathic product of Example 14 as above described, recurrence was significantly reduced in so far as in over 90% of individuals, ulcer recurrence in both number and frequency was halved with respect to the personal average of each individual. In fact, those who manifested a plurality of aphthae about every 15 days, noted after treatment with the solution of the invention that they reappeared surprisingly after not less than about two months and were fewer in number; after a subsequent treatment with the solution of the invention the aphthae surprisingly reappeared after not less than about six months and were even fewer in number.
Hence, the homeopathic product of the invention has proved to be particularly indicated in the treatment of aphthous stomatitis, enabling pain to be rapidly mitigated and above all to heal aphthae and reduce their onset in terms of number and frequency with an efficacy never before noted, neither with known supplements nor with the components a) and b) consumed singly.
Moreover, it was found that the above indicated dosages also proved to be suitable for children aged 5 and upwards, demonstrating the optimal tolerability of the homeopathic product of the invention as well as its confirmed effectiveness.
Example 16
Evaluation of the results obtained by sublingual administration of the homeopathic product of Example 14 in children
Although all the formulations and homeopathic products prepared above were shown to be effective in the paediatric treatment of aphthous stomatitis, it was chosen to report the results attained with the homeopathic product of Example 14 as it enabled optimal results to be obtained according to all the considered viewpoints.
A panel of 20 children aged between 2 and 5 years affected by recurrent aphthous stomatitis were selected for whom the treatment with neither the known supplements also containing Zn and Mg nor treatment with a Zn salt of 2,3,4,5,6- pentahydroxyhexanoic acid and a Mg salt of 2,3,4,5, 6-ρentahydroxyhexanoic acid taken alone and separately gave results of any kind.
To these 20 children 10 drops of the homeopathic product of Example 14 were administered sublingually 3 times a day for 5 days.
4-6 hours after the first consumption, 85% of said children noted a relief of pain caused by the aphthae and the ulcer healing beginning.
After 1 day, 100% of said children no longer felt any pain, while in 75% the aphthae had already completely healed.
One year after starting the treatment with the homeopathic product of Example 14 as above described, recurrence was significantly reduced in so far as in over 95% of the children, ulcer recurrence in both number and frequency was halved with respect to the personal average of each child. In fact, those children who manifested a plurality of aphthae about every 15 days, noted after treatment with the solution of the invention that they reappeared surprisingly after not less than about two months and were fewer in number; after a subsequent treatment with the solution of the invention the aphthae surprisingly reappeared after not less than about six months and were even fewer in number.
Hence, the homeopathic product of the invention has proved to be particularly indicated in the paediatric treatment of aphthous stomatitis, enabling pain to be rapidly mitigated in children and above all to heal aphthae and reduce their onset in terms of number and frequency with an efficacy never before noted, neither with known supplements nor with components a) and b) consumed singly. From the detailed description and from the given working examples, the advantages achieved by the described solution, obtained according to the present invention, are evident. In particular, in the case of both adults and children the synergy of the two components has enabled the disadvantages associated with the products of the known art to be overcome, as well as to effectively and rapidly heal the ulcers, thus significantly reducing their subsequent onset over time both in terms of the number of simultaneous aphthae and their occurrence frequency. A remedy has therefore been found for healing aphthous stomatitis which is well tolerated by the body to the extent that it can be used in both adults and children.
Claims
1. A solution comprising: a) a zinc salt of a polyhydroxy acid having π carbon atoms, and b) a magnesium salt of a polyhydroxy acid having m carbon atoms, wherein n and m are, independently of each other, an integer from 3 to 10 and the components a) and b) are in a v/v ratio of 10:1 to 1 :10.
2. The solution according to claim 1 , wherein the components a) and b) are in a v/v ratio of 5:1 to 1 :5.
3. The solution according to claim 2, wherein the components a) and b) are in a v/v ratio of 2:1 to 1 :2.
4. The solution according to claim 3, wherein the components a) and b) are in a v/v ratio of 1 :1 ,
5. The solution according to any one of claims 1-4, wherein n and m are, independently of each other, an integer from 5 to 8.
6. The solution according to any one of claims 1-5, wherein n and m are equal to each other.
7. The solution according to claim 6, wherein both n and m are 6.
8. The solution according to any one of claims 1-7, further comprising at least one inorganic magnesium salt and at least one inorganic zinc salt.
9. The solution of claim 8, wherein said at least one inorganic magnesium salt and at least one inorganic zinc salt are, independently of each other, chloride, sulphide or carbonate.
10. The solution according to any one of claims 1-9, in the form of an alcoholic solution.
11. The solution according to any one of claims 1-10 for use as a medicament.
12. Use of the solution according to any one of claims 1-10 for preparing a medicament for the treatment of aphthous stomatitis.
13. The use according to claim 12, wherein said medicament is to be administered sublingually.
14. A sublingual formulation comprising the solution according to any one of claims 1-10 and suitable pharmaceutically acceptable vehicles.
15. Use of the solution according to any one of claims 1-10 for preparing a homeopathic product for the treatment of aphthous stomatitis.
16. The use according to claim 15, wherein said homeopathic product is to be administered sublingually.
17. The use according to claim 15 or 16, wherein said homeopathic product is for the paediatric treatment of aphthous stomatitis.
18. A sublingual homeopathic product comprising the solution according to any one of claims 1-10 and suitable homeopathically acceptable vehicles.
19. The sublingual homeopathic product according to claim 18, wherein in said solution the components a) and b) are present independently of each other in homeopathic dilutions from 2 CH to 7CH.
20. The sublingual homeopathic product according to claim 19, wherein said solution additionally comprises at least one inorganic magnesium salt and at least one inorganic zinc salt, each independently of each other in homeopathic dilutions from 5 DH to 10 CH.
21. The sublingual homeopathic product according to any one of claims 18-20, wherein in said solution the components a) and b) are salts of a polyhydroxy acid having 6 carbon atoms.
22. The sublingual homeopathic product according to claim 21, wherein said solution is an alcoholic solution comprising the components a) and b) in a v/v ratio of 1 :1 , double magnesium calcium carbonate, and zinc sulphide.
23. The sublingual homeopathic product according to claim 22, wherein said solution is an alcoholic solution comprising a Zn salt of 2,3,4,5,6- pentahydroxyhexanoic acid 3CH and a Mg salt of 2,3,4,5,6-pentahydroxyhexanoic acid 3CH in a 1 :1 v/v ratio, double magnesium calcium carbonate 8CH, and zinc sulphide 8DH.
24. The sublingual homeopathic product according to any one of claims 18-23, for the paediatric treatment of aphthous stomatitis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000070A ITBO20090070A1 (en) | 2009-02-12 | 2009-02-12 | DRUG FOR AFTOSA STOMATITIS |
PCT/IB2010/050609 WO2010092534A1 (en) | 2009-02-12 | 2010-02-10 | Compositions for the treatment of aphthous stomatitis |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2396009A1 true EP2396009A1 (en) | 2011-12-21 |
Family
ID=41061080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10708593A Withdrawn EP2396009A1 (en) | 2009-02-12 | 2010-02-10 | Compositions for the treatment of aphthous stomatitis |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2396009A1 (en) |
IT (1) | ITBO20090070A1 (en) |
WO (1) | WO2010092534A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2388281B1 (en) | 2010-12-27 | 2013-10-01 | Laboratorios Viñas S.A. | Pharmaceutical composition comprising hyaluronic acid and a zinc compound and stick with stick and corresponding preparation procedure |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0641559A1 (en) * | 1993-09-07 | 1995-03-08 | L'oreal | Nail polish remover |
CN1236632A (en) * | 1998-05-22 | 1999-12-01 | 广州医学院第二附属医院 | Medicinal composition for treating recurrent aphthae |
CN1545944A (en) * | 2003-12-08 | 2004-11-17 | 孙善伟 | Sporting drink containing sugar, electrolyte and microelement |
WO2010081126A2 (en) * | 2009-01-12 | 2010-07-15 | Wyeth Llc | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847083A (en) * | 1986-04-02 | 1989-07-11 | Dermasciences, Inc. | Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith |
US5981499A (en) * | 1998-02-20 | 1999-11-09 | Atlantic Biomed Corporation | Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa |
EP0960572A1 (en) * | 1998-05-12 | 1999-12-01 | N.V. Nutricia | Nutritional composition for the treatment of pressure ulcers |
RU2004137651A (en) * | 2001-06-07 | 2005-10-10 | Чю Консалтинг Инк. (US) | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF APHTHIC ULCERS AND VIRUSES OF HERPES SIMPLEX VIRUS |
US6660293B2 (en) * | 2001-06-29 | 2003-12-09 | Everett Laboratories, Inc. | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
CN1303989C (en) * | 2004-10-25 | 2007-03-14 | 北京科信必成医药科技发展有限公司 | Zinc gluconate oral disintegrating tablet and its preparation process |
EP1814540A2 (en) * | 2004-11-16 | 2007-08-08 | Nu-Tein Co., Inc. | Compositions useful to treat ocular neovascular diseases and macular degeneration |
US20060198806A1 (en) * | 2005-03-04 | 2006-09-07 | Reilly Christopher A | Capsaicinoid decontamination compositions and methods of use |
US20070048387A1 (en) * | 2005-09-01 | 2007-03-01 | Edwards Jeffrey D | Tissue disruption treatment and composition for use thereof |
JPWO2008075621A1 (en) * | 2006-12-20 | 2010-04-08 | 協和化学工業株式会社 | Antacid |
CN101181279A (en) * | 2007-10-16 | 2008-05-21 | 黑龙江海昌生物技术有限公司 | Arificial tears containing trehalose as well as preparation and application method thereof |
-
2009
- 2009-02-12 IT IT000070A patent/ITBO20090070A1/en unknown
-
2010
- 2010-02-10 EP EP10708593A patent/EP2396009A1/en not_active Withdrawn
- 2010-02-10 WO PCT/IB2010/050609 patent/WO2010092534A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0641559A1 (en) * | 1993-09-07 | 1995-03-08 | L'oreal | Nail polish remover |
CN1236632A (en) * | 1998-05-22 | 1999-12-01 | 广州医学院第二附属医院 | Medicinal composition for treating recurrent aphthae |
CN1545944A (en) * | 2003-12-08 | 2004-11-17 | 孙善伟 | Sporting drink containing sugar, electrolyte and microelement |
WO2010081126A2 (en) * | 2009-01-12 | 2010-07-15 | Wyeth Llc | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin |
Non-Patent Citations (2)
Title |
---|
MOUSAVI F ET AL: "Homeopathic treatment of minor aphthous ulcer: a randomized, placebo-controlled clinical trial", HOMEOPATHY, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 98, no. 3, 1 July 2009 (2009-07-01), pages 137 - 141, XP026390390, ISSN: 1475-4916, [retrieved on 20090730] * |
See also references of WO2010092534A1 * |
Also Published As
Publication number | Publication date |
---|---|
ITBO20090070A1 (en) | 2010-08-12 |
WO2010092534A1 (en) | 2010-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070292493A1 (en) | Pharmaceutical composition and method for the transdermal delivery of calcium | |
EP0942720B1 (en) | Use of metal complexes to treat gastrointestinal infections | |
AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
TW200524585A (en) | Human β-defensin secretion promoter | |
US6316008B1 (en) | Combination of zinc ions and vitamin C and method of making | |
US20040170701A1 (en) | Pharmaceutical composition comprising copper, salicylic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection | |
US20170080025A1 (en) | Effervescent gargle tablet and method of using same | |
Piguet et al. | Pyogenic granuloma-like lesions during capecitabine therapy. | |
WO2007108712A1 (en) | Kit and method for treating or preventing anemia caused by iron deficiency | |
US6805875B2 (en) | Composition and method for treating diaper rashes and skin irritations caused by acidic secretions | |
WO2010092534A1 (en) | Compositions for the treatment of aphthous stomatitis | |
JPH11130669A (en) | Amino acid-based nutrient preparation for preventing/ treating bedsore | |
US4539315A (en) | Sublingually absorbable nontoxic aspirin composition | |
JPS6054932B2 (en) | therapeutic composition | |
Lansford Jr et al. | Effects of asparagine and other related nutritional supplements upon alcohol-induced rat liver triglyceride elevation | |
EP0938900A1 (en) | Preventives/remedies for stomatitis | |
Walan et al. | Metabolic consequences of reduced gastric acidity | |
US2159214A (en) | Double salt of calcium ascorbate and calcium acetylsalicylate and process of making same | |
Norman et al. | Effect of supplements of zinc salts on the healing of granulating wounds in the rat and guinea pig | |
US4446132A (en) | Nontoxic aspirin composition | |
JP6771274B2 (en) | Oral composition | |
JPH03504502A (en) | Compositions for administering therapeutically active compounds | |
WO2009031922A1 (en) | Tablet for prophylaxis and treatment of dental and periodontium diseases | |
US20120107419A1 (en) | Oral rinse formulation and method of use | |
US20150024070A1 (en) | Ingestible canker sore treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110912 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140910 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150321 |